secwatch.observer — SEC 8-K summary
======================================

Issuer:     PharmaCyte Biotech, Inc. (PMCB)
CIK:        0001157075
Form:       8-K
Filed at:   2021-07-06T23:59:59+00:00
Accession:  0001683168-21-002825
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PharmaCyte shareholders approve 50B common share authorization increase and bylaw amendment
--------------------------------------------------------------------------------

- Authorized common stock increased to 50 billion shares ($0.0001 par); preferred stock to 10 million shares.
- All seven director nominees elected; broker non-votes of ~701M shares.
- 2021 Equity Incentive Plan approved: 565.7M for, 116.4M against, 20.6M abstain.
- Armanino LLP ratified as independent auditor for FY ending April 30, 2022.
- Bylaw Amendment No. 4 adopted, adding cumulative voting rights for directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157075/000168316821002825/0001683168-21-002825-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157075/000168316821002825/pharmacyte_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-21-002825

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer